STAT3 and cancer: We demonstrated that 2G8 treatment significantly reduced the activity of STAT3 in PDA cancer cells in vitro and in vivo by downregulating stromal IL‐6, and therefore, TGFβ is a potential target, the blocking of which can interrupt this stromal tumorigenic signal.